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On the growth rates of human malignant tumors:
Implications for medical decision making
Sten Friberg
Testicular carcinomas, pediatric tumors and some mesenchymal tumors are examples of rapidly proliferating cell populations,
for which the tumor volume doubling time (TVDT) can be counted in days. Cancers from the breast, prostate and colon are
frequently slow-growing, displaying a TVDT of months or years.
Irrespective of their growth rates, most human tumors have been found: to start from one single cell, to have a long sub-clinical
period, to grow at constant rates for long periods of time, to often start to metastasize even before the primary is detected, to
often have metastases that grow at approximately the same rate as the primary tumor.
The recognition of basic facts in tumor cell kinetics is essential in the evaluation of important present-day strategies in
oncology. Among the facts emphasized in this review are:
– Screening programs. Most tumors are several years old when they become detectable by present-day diagnostic methods. This
makes the term 'early detection' questionable.
– Legal trials. The importance of so-called doctor's delay is often discussed, but the prognostic value of "early" detection is
overestimated.
– Analysis of clinical trials. Analysis of clinical trials may be differentiated depending on the growth rates of the type of
tumor studied. Furthermore, uncritical analysis of survival data may be misleading if the TVDT is not taken into
consideration.
– Analyses of epidemiological data. If searches are made for the causes of malignant tumors in man, the time of exposure
must be extended far back in the subject's history.
– Risk estimations by insurance companies. For the majority of human cancers, the 5-year survival rate is not a valid
measurement for cure.
Thus, basic knowledge of tumor kinetics may have important implications for political health programs, legal trials, medical
science and insurance policies.
Rozrost nowotworów z∏oÊliwych u ludzi
Implikacje dotyczàce podejmowania decyzji
Raki jàder, nowotwory dzieci´ce i niektóre guzy mezenchymalne to przyk∏ady bardzo szybko namna˝ajàcych si´ populacji
komórek, w przypadku których czas do podwojenia obj´toÊci guza (tumour volume doubling time – TVDT) bywa wyra˝any
w dniach. Z drugiej strony raki piersi, gruczo∏u krokowego czy jelita grubego rosnà powoli, a ich TVDT wyra˝a si´
w miesiàcach, a nawet w latach.
Niezale˝nie od dynamiki rozrostu wi´kszoÊç nowotworów napotykanych u ludzi posiada nast´pujàce cechy: wywodzi si´ z jednej
komórki, charakteryzuje si´ d∏ugim przebiegiem bezobjawowym, rozrasta si´ w jednostajnym tempie przez d∏ugi czas, cz´sto
daje przerzuty, zanim dojdzie do rozpoznania guza pierwotnego, cz´sto daje przerzuty charakteryzujàce si´ takim samym
tempem wzrostu jak guz pierwotny.
ZnajomoÊç podstawowych elementów kinetyki guza jest niezb´dna dla wypracowania wspó∏czesnej strategii post´powania
w nowotworach. W niniejszej pracy po∏o˝ono szczególny nacisk na nast´pujàce elementy:
– Programy przesiewowe. W momencie, kiedy przy u˝yciu nowoczesnych technik mo˝na stwierdziç obecnoÊç nowotworu,
rozrasta si´ on ju˝ zazwyczaj od kilku lat. Podwa˝a to zasadnoÊç terminu „wczesne rozpoznanie”.
– Zagadnienia medyko-legalne. Cz´sto rozwa˝a si´ znaczenie tak zwanego „opóênienia zawinionego przez lekarza”, ale
w istocie znaczenie prognostyczne „wczesnego” rozpoznania jest znacznie przeceniane.
Department of Oncology
Karolinska University Hospital
Stockholm, Sweden
Introduction
In 1997, Stefan Mattson and I published a review on the
growth rates of human malignant tumors [1]. Since then,
further information and more models for growth curves
have been published. Upgrading of the previous review is
thus of timely importance. The purpose of this review is to
consider the gross growth rates of various human
malignancies, as studied in their hosts. It will not deal
with in vitro studies, or studies in animals, since their
relevance for human spontaneous malignancies is
questionable. Nor will it deal with experimental studies in
humans (i.e. labelling indicies, incorporation of radio-
labeled nucleotides, immunological markers, etc) since
these studies do not take cell loss (mainly through
apoptosis) into consideration [2]. In this review, the
growth rate is defined as the rate of increase of volume
(or the number of cells) in relation to time. It is based on
studies of more than 2,500 individual cases, with a total of
more than 7,000 observations of the growth rate.
Data mining
The database “Medline” was searched back to the
beginning of 1966. Search words were the same as the
key words in this review. Articles prior to 1966 were
identified through perusal of the reference lists in the
articles found. Exclusion criteria of the articles were
reports on individual cases, or cancers with uncommon or
unclear pathology, or cases with only a few observations.
If the examination methods were other than
radiological, they were also excluded. Special focus was
placed on reports dealing with cancers of the breast,
cancers of the lung, and ocular malignant melanomas.
Whenever the suspicion has arisen that the same patient
cases had been published more than once, that particular
clinical material is referred to only once.
Background
M o n o c l o n a l i t y
A primary tumor starts from one single cell, the same
way that all human beings originate from a single cell:
the fertilized egg. The notion that a tumor develops from
a single cell (monoclonality) was anticipated by Virchow
in 1862 [3]. One hundred years later, in 1962, Walden-
ström gave the hypothesis support from studies on human
multiple myeloma [4]. Today, monoclonality has been
shown for the majority of human malignant tumors [5-8].
Even multicentric tumors – such as cancer of the urinary
bladder [9] or cancer of the breast [10] – have been shown
by modern methods in molecular genetics to be originally
monoclonal.
Also, even tumors in paired organs – like the testes –
seem to stem from one basic genetic alteration during
embryogenesis [11, 12]. The same genetic alteration also
appears to be the underlying cause of extra-gonadal germ
cell tumors (in the thymus or the pineal gland) [13].
Heterogeneous clones are likely to occur later during the
life-span of a tumor. It will be shown in this review that
most malignant tumors in humans are many years old
when clinically detectable. Polyclonality at the time of
diagnosis does therefore not contradict a monoclonal
origin: the tumor cell population has had ample time to
diversify during the pre-clinical period. To make
a comparison, every newborn being is polyclonal, but its
origin (the fertilized egg) is monoclonal. Attempts at
disproving monclonality of origin for clinical tumors will
always be hampered by the fact that diagnosable tumors
are not at their origin.
C e l l  k i n e t i c s
The first tumor cell multiplies exponentially with time:
1-2-4-8-16-32 and so forth. If the tumor cells have
a diameter of 10 µm, the clone will have reached a volume
of approximately 1 cm3 after 32 cell generations. If the
tumor cells are 25 µm in diameter, 26 doublings are
required to reach that volume, and at that size, it consists
of 109 cells.
For calculations of growth curves in this review the
following simplifications have been made: tumor cells
have a diameter of 10 µm [10-6 meters], macroscopic
tumors consist of tumor cells only, and the tumor cells are
densely packed to fill completely the sphere. The cellular
composition of tumors will be discussed below. If the size
of a tumor is given in two dimensions [cm x cm] and is
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– Analiza badaƒ klinicznych. Analiz´ badaƒ klinicznych mo˝na zró˝nicowaç w zale˝noÊci od dynamiki wzrostu badanego
typu nowotworu. Co wi´cej, bezkrytyczne podejÊcie do wyników badania, przedstawionych w aspekcie d∏ugoÊci prze˝ycia,
mo˝e byç bardzo mylàce, jeÊli nie bierze si´ pod uwag´ TVDT.
– Analiza danych epidemiologicznych. JeÊli poszukuje si´ czynników odpowiedzialnych za wystàpienie nowotworu u danego
chorego, to analizà nale˝y objàç okres si´gajàcy nawet wiele lat wstecz.
– Ocena ryzyka prowadzona przez ubezpieczyciela. W przypadku wi´kszoÊci nowotworów spotykanych u ludzi pi´cioletnie
prze˝ycie nie jest adekwatnym miernikiem wyleczenia.
Podsumowujàc, mo˝na stwierdziç, ˝e znajomoÊç kinetyki nowotworu ma istotne implikacje nie tylko w zakresie planowania
narodowych strategii zdrowotnych, ale równie˝ podczas prowadzenia spraw sàdowych dotyczàcych post´powania medycznego,
w kontekÊcie badaƒ naukowych, a nawet w odniesieniu do ubezpieczeƒ zdrowotnych.
Key words: neoplasm, human, growth rate, doubling time, diagnostic level, lethal burden, period of risk
S∏owa kluczowe: nowotwór, ludzie, dynamika wzrostu, czas podwojenia, poziom diagnostyczny, ÊmiertelnoÊç, okres
ryzyka
plotted against time, the curve depicted in Figure 1A is
obtained. It gives the reader the impression that a tumor
grows at an accelerating speed. But this is an illusion
which will be commented on below. The increase in the
number of cells in a tumor is determined mainly by three
principal parameters [14]: 1. The cell cycle time of the
proliferating cells, 2. The fraction of cells proliferating, 3.
The amount or fraction of spontaneous cell loss. The
spontaneous cell loss in vivo may be as high as 50% [14] in
each cell cycle or even higher [15] and is therefore of
profound importance for the growth rate. Refsum and
Berdal [15] calculated the cell loss in 61 cases of
oropharyngeal cancers to be as high as 96%, explaining
the slow increase in net volume.
Related to time, the net growth of the tumor volume
is fairly constant during the visible stage [16-35]. Plotted
on a semi-logarithmic scale, it is linear. The inclination of
the slope may be called the tumor volume doubling time
(TVDT). This is shown in Figure 1B. The growth curve in
Figure 1B is identical to that in Figure 1A, except that the
size of the tumor has been given not as the diameter [in
centimeter] but as the number of cells on a logarithmic
scale. Tumors grow in 3 dimensions, not 2. In this review,
linear growth is defined as a constant increase of tumor
volume on a logarithmic scale, in relation to time. The
distinction between Figures 1A and 1B are not always
made. This has probably led to one of the myths in
oncology, which will be examplified below.
G r o w t h  c u r v e s
An early contribution to the theory of growth curves –
although not intended for tumors – was made by
Gompertz in 1825 [36]. Several other mathematical
models useful for studying tumor growth exist [37-40].
Most growth curves are characterized by an upper
horisontal asymptote. For human malignant tumors, this
upper horisontal asymptote is the upper limit which the
cancer cannot exceed because the tumor burden has
become lethal to its host. This limit has been termed the
"lethal burden", and it is illustrated in Figure 2, where
the period during which human tumors are measurable in
vivo is that above the detection level. More recent growth
models are published by Plevritis [41], by van Leeuwen et
al [42], and by Kopans et al [43].
The growth curves in Figure 2 were obtained in the
following way: the slope of the linear growth curve was
calculated for 3 different arbitrary TVDTs (10, 100 and
150 days). Each curve was then inserted as a straight
line in the interval from 109 to 1011 cells (measurable
phase). This is the interval in which human tumors are
measurable, and where linear growth has been found to
occur. Each curve was then extrapolated back to the one-
cell origin, and adjusted in relation to time. From 1011
to 1013 cells, the estimated asymptote is then added.
In Figure 2, a retardation of growth (deceleration) is
seen at the upper limit. This is likely to be true for the
primary tumor, due to diminishing nutrients, blood
supply, growth factors, hormones and so forth. Such
measurements, however, are rare, because the patient
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Figure 1.
Figure 1 A. Gross growth rate of a tumor.
Abscissa: Number of cell divisions.
Ordinate: Tumor size (diameter in centimetres).
Note the number of cell divisions required for the tumor to reach diagnostic level (0.2 – l cm in diameter). The
pitfall of plotting tumor growth on a non-logarithmic scale gives the false impression that the tumor grows at
an increasing speed.
Figure 1 B. Gross growth rate of a tumor.
Abscissa: Number of cell divisions.
Ordinate: Number of cells (logarithmic scale).
The growth rates are identical in Figures 1A and 1B, but the units on the ordinates are different.
It takes more than 30 doublings for the tumor cells to reach a population size of 109 cells.
At that point the tumor has a diameter of 1 cm and it weighs 0.52 gram. With a TVDT of 150 days, and
assuming a constant generation time, the tumor is then around 12 years old.
The straight line indicates a constant growth rate, in contrast to the false impression that Figure 1A gives.
is close to death. It would be unethical to investigate
for only scientific purposes a patient who is beyond
treatment. If extrapolation back to the one-cell origin
starts near the asymptotic level, this can explain the
absurd results indicating that the tumor started to grow
some 30 years before the patient was born. The majority
of human malignant tumors display constant growth rates
– albeit individually highly different – in the medium size
range (107-1011 cells).
However, when the total number of tumor cells in
a patient are considered, then the contribution by micro-
scopical metastases should be included. But their weight
will never be known. If they are added, the curve will
become straighter and steeper. It may be argued that
since the growth rate during the pre-clinical period is
not known, the extrapolation back to the one-cell level
is uncertain. For the growth rate of a tumor during the
pre-clinical period, three theoretical possibilities exist: 1.
it can be faster than, 2. it can be identical to, or 3. it can be
slower than the growth rate during the visible phase, see
Figure 3.
Facing these three possibilities, the present author
has chosen the intermediate one (= identical growth
rate). In Figure 2 the total burden is provided exclusively
by the primary tumor. In the clinical setting, a tumor with
a volume of 1 cubic centimeter (=109 cells) is regarded as
a relatively small tumor. It is at that size that a tumor
may give rise to the first symptoms. It is also at that size
that a tumor may become detectable by palpation, or by
the use of tumor markers such as Prostate Specific
Antigen (PSA) [44], or on radiographs.
C e l l u l a r  o r i g i n s  o f  m e t a s t a s e s
Metastases can also be assumed to start from one single
cell, or a small complex of cells. The TVDT of a se-
condary tumor has likewise been found to be constant
during the first part of the visible phase, and thus linear
on a semi-logarithmic scale. Therefore, determinations
of the TVDT of a secondary tumor followed by extrapo-
lation back to the one-cell origin, may allow estimation of
the starting time of that secondary tumor.
There is a widespread opinion among physicians that
metastases grow faster than their primaries, through
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Figure 2. Growth rates for three different tumors.
Abscissa: Time (years). Ordinate: Number of tumor cells (logarithmic scale).
The diagnostic level (from 107 to 109 cells), and the lethal burden (1012-1013 cells, or 1 kilogram –
10 kilograms) limit the visible phase of a human tumor.
The three tumors have been given TVDTs of 10, 100 and 150 days respectively.
Symbols:
........ = invisible phase (extrapolated)
– = visible (and measurable) phase
------ = estimated asymptote
The number of cells is assumed to be produced by the primary tumor alone. If the addition to
the total tumor burden from the metastases is also included, the curve approaches a straight line.
Figure 3. Hypothetical growth during the pre-clinical phase.
Abscissa: Time (years).
Ordinate: Number of tumor cells (logarithmic scale).
A: Slower than,
B: Equal to,
C. Faster than during the measurable phase (2 x 107-1011 cells)
a selection of the fast-growing clones. This may be true,
but support for this idea in the medical literature is scarce.
A more likely explanation is that the growth rates of the
metastasis are plotted on a arithmetic scale and not on
a logarithmic. In the clinical setting, the size of a tumor is
usually given in only 2 dimensions, whereas growth is 3-
dimensional.
Whenever growth rates of tumors are studied, the
authors and readers must think in terms of logarithms. If
a sphere has increased its size from 1 to 2 centimeters in
diameter, it has not doubled its volume; it has increased
its volume 8 times.
Methods
R a d i o l o g i c a l
The TVDT of various untreated solid malignant human tumors
has been the subject of several studies, and serial radiograms
have usually been the method of choice. The growth rates of
primary cancers of the breast can be directly observed with
mammography. Likewise, the growth rates of primary cancers
from the lung can be directly followed from serial X-ray
examinations of the chest.
M e t h o d o l o g i c a l  e r r o r s  i n  d i a g n o s t i c
r a d i o l o g y
The exact measurement of the volume of tumors from
radiograms can be difficult. Irregular shapes, unsharp boundaries
and inhomogeneity are some of the major obstacles. In a careful
analysis of the possible errors, Brenner et al [25] concluded that
the methodological error for a single determination amounted to
±11% of the volume.
C e l l u l a r  c o m p o s i t i o n  o f  m a c r o s c o p i c
t u m o r s
Macroscopic tumors are not composed of cancer cells alone.
Stroma, vessels, blood and other non-neoplastic elements
contribute to the volume. It can be assumed, however, that for
a given tumor the proportion of neoplastic to non-neoplastic
cells remains constant during long periods of growth.
If a macroscopic tumor with a diameter of 1 cm consists
of tumor cells alone, it must have gone through around 30
doublings from the first cell. If the tumor consisted also of 50%
non-tumorous cells, it would have reached 1 cm in diameter in
26 doublings of tumor cells. Thus, even a 1:1 proportion of
tumor cells to non-tumorous cells has only a marginal influence
of the tumor volume on the time scale.
L e v e l s  o f  r a d i o l o g i c a l  d e t e c t i o n
The crucial point is the minimal detection level of radiologists.
This was experimentally tested by Spratt et al [18]. They placed
lucite balls having a radiopacity approximating that of solid
tumors and ranging in diameter from 1.6 to 12 mm randomly
upon the posterior and anterior thorax of patients. Radiographs
were taken and examined by a group of radiologists. The
conclusions were as follows. "Radiologists could distinguish 10-
12 mm diameter balls regardless of their location. 6 mm balls
could be detected when the shadow was in a favourable site,
and 3 mm shadows could only be found when the radiologist
was shown precisely where to look. Radiopacities smaller than 3
mm were indistinguishable." For mammography, the lowest level
of detection is stated to be 2.1 mm [45]. For conventional X-rays
of the lungs, 6 mm has been stated to be the lower detection
limit [46].
E r r o r s  i n  c a l c u l a t i o n  o f  T V D T
The basis for this calculation has been clearly stated by Shackney
et al [47]: "Because the number of cell doublings in the
subclinical stage of growth is so large, any error in calculating the
doubling time that might be introduced by underestimating
tumor size at diagnosis would be relatively small. For example, if
the tumor at diagnosis consisted of 1 x 1011 cells (= 100 g of
tissue) instead of 1 x 109 cells (= 1 g), the actual number of
doublings would be a little more than 36 instead of 30,
introducing an error of little more than 20% in the doubling
time calculation."
E r r o r s  i n  e x t r a p o l a t i o n s
The nature of exponential growth places a practical limitation on
the magnitude of possible errors in determination of tumor
volume. An error by a factor of 2 is compensated for by one
single cell population doubling. An error by a factor of 100 is
compensated for by only 6.75 doublings. Thus, even a rather
large error in measurement and calculation of the volume leads
to a much smaller error in the estimation of the duration. Any
inaccuracy in determination of growth rate at worst only
produces a scale error not affecting the order of events.
If the point of origin (= the first cell) is obtained by
extrapolation backwards in time, the position of that point on the
time scale will depend on whether extrapolation starts from the
linear visible phase (2 x 107 to 1011) or from the brief asymptotic
phase. In this review, all extrapolations have been performed
from the visible phase, assuming a constant growth rate.
All estimations of the duration of the pre-clinical phase
are handicapped by the fact that the growth rates are not known.
Comparisons with experimental tumors in animals or in vitro
situations are questionable, and therefore omitted here. Much
of the confusion regarding various growth curves is due to the
fact that many investigators try to apply one single formula to
three basically incommensurable types of tumors: 1. Human
spontaneous tumors, 2. Experimentally induced tumors in
animals, and 3. Tumors grown in vitro. Trying to unify these
three is not only a gross oversimplification: it is incorrect.
Experimentally induced tumors have different properties than
spontaneous tumors, and cells growing in vitro can be regarded
as laboratory artefacts. They are selected to grow under highly
specialized conditions, and also for their fast growth rates (in
order to give fast results?).
As mentioned, three theoretical possibilities exist for the
growth rates of spontaneous human tumors during the pre-
clinical phase as was shown in Figure 3. An identical growth
rate was chosen, basing the choice on values from the
measurable phase.
Evidence has been presented supporting slower as well as
faster growth rates during the pre-clinical phase. Slower growth
rates (curve A in Figure 3) may occur prior to the production of
angiogenetic factors by the tumor cells. During the quiscent
period, the production of new cells is counteracted by the loss of
cells through apoptosis, resulting in a slow or no net increase in
the volume of the tumor [2]. Evidence for faster growth rates
during the pre-clinical phase (curve C in Figure 3) is based on
indirect calculations [45]. The reader is referred to Steel and
Lamerton [38], Dethlefsen et al [39] and Steel [40] for a more
detailed discussion of these models and on the possible errors in
extrapolations from growth curves.
Results
H i s t o r i c a l  c o m m e n t s
The first observations were made by Collins et al [16],
who studied the growth rates of pulmonary metastases
from a variety of primary tumors. Their initial obser-
vations resulted in the identification of three fundamental
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principles for the growth rates of human tumors: 1. It is
constant for long periods of time, 2. It is often slow, 3. It
varies from one histological type to another.
Collins’ three principles have been repeatedly
confirmed [17-35]. Wilms’ tumor [32], acute leukemias
[48] and non-seminomatous germ cell tumors (NSGCT)
[49] are examples of rapidly (a TVDT of days) pro-
liferating cell populations. Most adeno-carcinomas and
some mesenchymal tumors have considerably slower
growth rates (a TVDT of months or years) [17-28, 30-
32, 34-37, 50-51].
L i n e a r i t y  o f  i n c r e a s e  i n  v o l u m e
Linearity of increase in volume on a logarithmic scale
has been observed for several types of human
malignancies. In many instances, linearity has been
maintained during several years, and with numerous
observations.
Examples of linear growth will be given later in this
article. Some representative cases have been selected to
illustrate this. Selection criteria have been: 1. Numerous
determinations of tumor volumes (usually more than
four), 2. Observation of growth rates over long periods
(years), 3. Well-defined histology of tumors, 4. No local or
general treatment. The first two criteria were utilized to
minimize methodological errors in extrapolations.
From the references in this review a total of 58
untreated primary tumors were found which where
measured more than four times during at least three
years. All 58 of these tumors show linearity of increase in
volume.
von Fournier et al [33] were able to follow 12 women
with untreated cancer of the breast for 3-9 years with 5 or
more mammograms in each case: all tumors showed
a linear increase in volume during the observation period.
Garland et al [19] studied primary pulmonary malignan-
cies in 41 patients over several years and noted linear
increase in volume. In one case, linearity was maintained
for 9 years. Spratt, Spjut and Roper [20] studying 118
cases with pulmonary metastases from various primary
tumors observed linear increase in volume with multiple
measurements for many years. Breur [23, 24] studying 16
cases of pulmonary metastases from mesenchymal malig-
nancies, noted linearity during the whole observation
period (years) for all cases. One patient was examined
radiologically 11 times during a 44 month period. All
measurements of tumor volume fell on a straight line [on
a logarithmic scale]. Fujimoto et al [51] studied cases
with renal cell carcinomas. In 6 cases the primary tumors
were followed, and in 12 (different) cases metastases to
the lungs were monitored. The growth rate showed great
interindividual variability, but in each case the growth
rate was constant during the observation period. In one
case, linearity of growth was noticed for all 7 measu-
rements during a period of 6 years. A remarkable case has
been published by Spratt and Ackerman [50]. They were
able to follow a patient with a well differentiated adeno-
carcinoma of the colon for more than 7.5 years. All of
their 9 observations on the growth rate fell on a straight
line. Numerous examples of cases displaying linear growth
will be found below. On the other hand, exceptions to
linear growth are common. Spontaneous regression, no
growth, irregular growth rates and accelerations of growth
can all occur. However, the general impression remains,
that most human malignancies grow at a slow and steady
rate for long periods of time during the clinical (and
measurable) phase.
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Figure 4. Growth rates for twelve cases with primary cancer of the breast.
Abscissa: Time.
Ordinate: Number of tumor cells (logarithmic scale).
Each curve represents one case. The solid line indicates the period of observation.
Dotted lines mark the invisible phase. Modified from von Fournier et al [33] with the kind permission
of the Lippincott-Raven Publishers.
S t u d i e s  o n  T V D T  o f  c a n c e r  o f  t h e  b r e a s t
Figure 4 shows the growth rates for 12 primary cancers of
the breast. All cases were untreated, and each patient
was examined radiologically at least five times. The
observation period ranged from 2 to 9 years. The curves
have been adjusted to the one-cell origin, which arranges
the curves in a "fan-like" fashion. Figure 4 shows the great
interindividual variability of the growth rates for different
cancers of the breast, with TVDTs ranging from 88 to
523 days. The average doubling time is 280 days, which
means that more than 18 years were required from the
first tumor cell (≈10 µm in diameter) to produce a tumor
with a diameter of 2 mm (= the lowest detection level).
The curves in Figure 4 have been redrawn from the
study by von Fournier et al [33]. In that study, there was
no correlation between the growth rate of the cancer and
the age of the patient at the time of diagnosis. The lowest
age of a patient when a cancer was detected was 36 years.
That cancer had a TVDT of 196 days, indicating that it
started to grow when the patient was around 20 years
old. The highest age of a patient at the time of diagnosis
was 70 years. That cancer had a TVDT of 297 days. The
smallest detectable cancer had a diameter around 2 mm
(≈107 cells). The largest cancer that was measured had
a diameter of around 45 mm (≈1011 cells). The fastest
growing cancer had a TVDT of 88 days and it was
detected in a woman when she was 55 years old. It was
observed for 4 years with five mammograms. The slowest
growing cancer had a TVDT of 521 days. This was
discovered in a woman when she was 60 years of age,
and it was observed for 8 years with 8 mammograms.
Table I gives a summary of TVDT for cancer of the
breast, as measured from serial mammograms. The table
is based on observations from more than 800 patients.
All patients were untreated. For obvioius reasons detailed
information of the histological classification is usually
not given, but the malignancy was confirmed, either
cytologically, histologically or at autopsy. Many of these
patients were followed for several years, and subject to
repeated mammograms. All tumors had diameters
between 2 mm and 10 cm. In this range the growth can be
expected to be linear before the asymptote in Figure 2 is
reached.
Only the five largest studies on cancer of the breast
have been included in Table I. Several authors give similar
figures, but their number of patients is lower, and their
results have therefore not been included [23, 24, 30, 45,
56-66]. Galante et al [67] reported observations on 196
cases with cancer of the breast. Their results were
presented in such a way that the median TVDT could
not be calculated, and their observations are therefore
not included.
When comparing the TVDT in individual patients,
considerable differences are found [see Figure 4].
However, relevant studies give results of the same order
of magnitude as the estimated TVDT of cancer of the
breast, as seen in Table I. In the five publications listed in
Table I, the TVDT values center around 180 days. The
exact median TVDT from the five publications in Table I
cannot be calculated, since the data presented are not
always complete, and they are also presented in various
different ways. So-called interval and inflammatory
cancers – which are fast-growing – are omitted by some
authors since these tumors are not measurable on
mammograms. On the other hand, cancers not showing
any increase in size at all during the observation period
(TVDT ≥5,000 days) are also excluded by some authors.
The proportion of fast-growing cancers to non- growing
cancers can not be calculated from data in the literature
because definitions of "fast" and "slow" vary from one
author to another. It can be assumed to be in the same
order of magnitude. It is therefore likely that the two
categories "fast" and "slow", when excluded, to some
extent compensate each other when the median value
of TVDT is estimated. Since approximately 32 cell
doublings, and 100% viability of the cells, are required
for the first cancer cell to reach a volume of 1 cubic
centimeter, a cancer of the breast with a TVDT of 150
days has an age of 12 years or more when discovered
clinically by palpation.
The smallest detectable cancer of the breast
detectable measures 2.1 mm [45]. With a TVDT of 150
days, such a cancer is 8 years old and it consists of 107
cells. An excellent mathematical model for invasive cancer
of the breast, which also takes ductal cancer in situ
(DCIS) into consideration, is given by Kopans et al [43].
An excellent mathematical algoritm for cancer of the
breast detected by mammography is given by Plevritis
[41].
S t u d i e s  o n  c a n c e r  o f  t h e  l u n g
The first reviews of cancers of the lung and their growth
rates was given by Geddes [68]. This elegant publication
has been confirmed several times. However, not all of
the published data lend themselves to comparison, since
the histopathology is not always given. Some of the studies
on histologically better defined primary carcinoma of the
lung are listed in Table II, in which 12 of the largest
studies are included.
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Table I. Growth rates for cancer of the breast
Estimated TVDT Number of Reference
(days) cases studied
105* 199 Kusama [52]
150† 200 Peer [53]
174† 122 Kuroishi [54]
212++ 147 von Fournier [33]
270* 158§ Arnerlöv [55]
*= median
†= geometric mean
+
+= arithmetic mean
§= four cases with infinite growth have been excluded
The mean TVDT for these cases cannot be calculated (for explanation,
see text). The estimated weighted median value is around 150 days. The
range varies from 30 days [52] to infinity [54]. The range has been
illustrated in Figure 4.
Table II is based on more than 300 completely
untreated patients. The histology of these tumors were
often determined at autopsy. The number of observations
of the volume of the tumor is at least 2, and in many
cases 5 to 10. Several of the patients were observed for
years or almost a decade, as will be illustrated later
(Figures. 5, 6 and 7). Median values for the TVDTs of the
various histological types can be estimated to be around
90 days for epidermoid carcinomas, 65 days for small cell
carcinomas, and 185 days for adenocarcinomas.
Growth rates for primary cancers of the lung are
illustrated in Figures 5 and 6. Figure 5 shows five cases
with epidermal carcinomas (non-small cell carcinomas,
NSCC), and Figure 6 shows four cases with adenocar-
cinomas. All cases were selected to illustrate constant
growth rates over prolonged periods of time, occasionally
more than 10 years.
Spratt, Spjut and Roper [20] noted: “The number
of years required for a cancer to grow from 100 to 109
cells is 7.8 years for an epidermoid carcinoma, and 22.5
years for an adenocarcinoma.”
This means, that if an adenocarcinoma with
a volume of 1 cm3 is found in the lung of a man 63 years
old, the tumor started to grow when he was around
40 years old, and it would still be invisible when he was
55 years old. That patient would reach a lethal tumor
burden from the time of diagnosis after 10 more
doublings of the tumor cells, i.e. when he is 69 years old.
If these somewhat theoretical figures are put into clinical
realities, both size at the time of diagnosis and the TVDT
have a profound influence on prognosis. If two smokers
both develop the first cell of lung cancer at the age of
40 years, and the TVDT is 30 days for one of them
(SCLC), and 300 days for the other (adenocarcinoma),
the first patient will reach diagnosible level after almost
4 years, whereas the other can be detected only after
30 years. The first patient will have an aggressive cancer at
44 years of age, and the other an almost benign tumor
at 70.
The latest reports on the growth rates of cancers of
the lung, where more modern and sensitive radiological
methods than conventional radiographs have been used
[74, 75, 46], indicate that small cancers grow at similar
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Table II. Growth rates for cancer of the lung divided according to
histological type TVDT (days)
Histological type Reference
Epidermoid Small-cell Anaplastic/ Adenocar-
Undifferentiated cinoma
70 (13) 93 (13) 118 (8) Spratt [20]
78 (8) 109 (7) 214 (11) Weiss [69]
79 (11) 71 (2) Schwartz [17]
80 (97) 207 (19) Charbit [70]
92 (16) 64 (23) 144 (21) Steele [28]
93 (6) 90 (9) 269 (7) Spratt [20]
95 (21) 39 (3) 61 (3) Chahinian [71]
103 (6) Meyer [27]
107 (7) 232 (5) Weiss [22]
126 (22) 123 (9) 219 (7) Garland [19]
141 (14) 46 (3) 86 (7) 257 (2) Mattson [72]
77 (12) Brigham [73]
Numbers within brackets denote number of cases. The range is not
given.
Only publications with five or more cases have been included.
Figure 5. Growth curves for five cases of primary epidermoid cancer of the lung.
Abscissa: Time.
Ordinate: Number of tumor cells (logarithmic scale).
Each curve represents one case, and each point one observation.
The three more rapidly growing tumors have been adjusted slightly in parallell to facilitate
visualization. Note that the observation extends over more than 10 years. The data have been
extracted and modified from Spratt & Spratt [20], Schwartz [17], and Brenner et al [25] with the kind
permission of the editors.
rates as bigger ones, again indicating that linearity of
growth is maintained over time.
S t u d i e s  o n  m a l i g n a n t  m e l a n o m a s
The ophtalmologists have given a very elegant
demonstration of how knowledge of tumor kinetics can
influence clinical practice. In 1980, McLean et al [76]
calculated that it took 7 years for a “small” (≤10 mm)
melanoma of the eye to grow to a “large” one (≥15 mm).
They observed a higher mortality rate during the first
two years after enucleation. They hypothesized that this
was due to dissemination during the operation. This
altered the treatment philosophy from the previous
extreme to the other; from “when in doubt, take it out” to
“avoid enucleation as long as possible, since it may harm
the patient”. The need for treatments other than surgery
became imminent. In 1985, Gass [77] in a study of 34
patients noted: “Each melanoma grew at a constant rate
that varied widely in different patients, ranging from 2
to 30 months”. The analysis did not indicate that
enucleation was responsible for dissemination of meta-
stases, rendering collegues uncertain of what to do with
their patients.
This is where tumor cell kinetics came into the
picture. Manschot and van Strik [78] in 1992 presented
a summary of the growth rates for 39 patients. 36 of the
melanomas had a TVDT of 60 days or more. Metastatic
death occurs after 40 doublings after the first cell. If the
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Figure 6. Growth curves for four cases of primary pulmonary adenocarcinoma.
Abscissa: Time.
Ordinate: number of tumor cells (logarithmic scale).
Each curve represents one case, and each point one observation.
Curves have not been fitted to the one-cell origin. Note the linearity for all the cases during the
observation period. Two cases are from Weiss et al [69]. The two others are from Spratt et al [20].
Modified and reproduced with the kind permission of the editors.
Figure 7. Growth curves for acinic cell cancers.
A. Logarithm of volume of a malignant tumor in proportion to time after onset. TDT = TVDT in this publication.
B. The onset time (10 µm) and the time when the tumor grew to 1 mm in diameter are calculated on the same graph paper.
From the publication by Umeda et al [82], reproduced by the kind permission of the author.
metastases were seeded during enucleation, it would take
60 x 40 days (around 7 years) to reach lethal burden.
Thus, enucleation could not be responsible for the
mortality during the first 6 years after treatment. All
deaths among patients earlier than 7 years post-
operatively must therefore be due to dissemination prior
to enucleation. And enucleation was again accepted as the
treatment of choice.
In a study of ocular malignant melanomas with
solitary metastases to the lungs in 45 patients, Ollila et al
[79] found the TVDT to be 66.9 days (range 14-287 days).
All patients underwent resection, and were followed until
death. A multivariate analysis showed that the only
prognostic variable was the TVDT. Patients with a TVDT
less than 60 days did not benefit from surgery. Finally,
Eskelin et al [80] in 2000 reported on 37 cases where they
tried to determine the time for the first metastasis in
patients with ocular malignant melanomas. The growth
rates of untreated metastases ranged from 34 to 220 days
with a median of 63. Eskelin’s et al data indicated that the
first metastases started to grow around 5 years before
the diagnosis was made. The growth rates for the
metastases had a mean TVDT of 63 days (range 34-220
days), which is remarkably similar to those of Ollila’s et al:
67 days (range 14-287 days).
Thus, calculations of the TVDT’s of ocular
malignant melanomas led to a series of evolutionary steps.
First, it re-established a discarded treatment of the
primary tumor. Second, it provided the identification of
patients who would benefit from resection of a solitary
metastasis. And third, the TVDT’s gave an explanation of
the natural history of the disease.
The growth rates for the primary of 17 ocular
malignant melanomas were presented by Augsburger et al
[81]: a mean of 205 days (range 23-540 days). The figures
are incorporated in Table III.
A c i n i c  c e l l  c a n c e r
Acinic cell cancer (ACC) is a very slow growing
malignancy from the salivary glands. The average interval
between initial treatment and the appearance of distant
disease is 8.1 years. Umeda et al [82] gave a TVDT of
393 days. All their tumors showed linearity of growth, in
some cases for up to 70 months and 14 measurements.
They calculated that: “the time of onset of pulmonary
metastases was much earlier (average of 227 months)
than the patient’s first visit. ACC growth rates are
included in Table III, and Umeda’s growth curves are
shown in Figure 7.
H e p a t o c e l l u l a r  c a r c i n o m a s
Since long, primary hepatocellular cancer has been the
most common malignant tumors in Asia and parts of
Africa. The frequency is now increasing also in the
Western Civilization [83]. The growth rates for these
cancers have been reported in three publications [84, 85,
86]. Kubota et al [84] gave a TVDT of 94 days (range
45-496 days) for their 49 cases. All growth curves were
straight lines. The other two publications gave similar
figures (see Table III).
S t u d i e s  o n  p u l m o n a r y  m e t a s t a s e s
The growth rates of primary tumors other than cancers of
the breast, cancers of the lungs and ocular malignant
melanomas have not been studied to the same extent.
The obvious reason is that there are few other malignan-
cies that lend themselves to accurate measurements of
the tumor volume.
However, the growth rates of solid human malignant
tumors originating from organs other than these can be
estimated indirectly by monitoring their metastases to
the lungs, where serial X-ray examinations allow
observations. This indirect estimation of the growth rates
of the primary tumor is based on the assumption that
metastases grow at rates similar to that of the primary
tumor. This supposition will be discussed below.
Table IV lists some of the histologically better
defined metastases which have been studied. The majority
of these originated from mesenchymal neoplasms – for
which no effective general therapy is available – or from
testicular tumors before the introduction of cis-platinum
treatment. In these studies, the growth rates were not
influenced by any systemic therapy.
Table IV also includes published data on more than
five cases studied by the same investigator. Singular
observations have been omitted. Growth rates for six
pulmonary metastases are illustrated in Figure 8. The
selection criteria were the same as for Figures 5 and 6.
In Figure 8 only four of the cases display linear
growth during the observation period. The other two
cases exemplify non-linear growth: one case showing
acceleration and the other retardation. It can be noted
that the retarding growth rate occurs when the volumes
are smaller than would be expected at the level of the
asymptote in Figure 2.
Two more cases of pulmonary metastases are
illustrated in Figures 9 and 10. These cases were selected
because they provide unusually beautiful examples of
linearity of growth. Both cases are from Breur [23]. One
explanation of the observed effect of radiotherapy on the
metastases is that it is a “partial response” and a true
effect on the tumor cell population. Another explanation
is that the radiotherapy diminishes the number of non-
neoplastic cells (lymphocytes, vascular endothelium, etc.),
leaving the tumor cells unaffected.
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Table III. Growth rates for three types of primary malignancies
Type TVDT +range Numer Reference
(days) of cases
Hepatocellular 94 (35-496) 49 Kubota [84]
” 102 (41-305) 15 Okazaki [85]
” 117 (29-398) 28 Sheu [86]
Acinic cell cancer 393 (86-1064) 30 Umeda [82]
Malignant melanoma 205 (23-540) 17 Augsburger [81]
(ocular)
Figure 9 shows one case of fibrosarcoma with two
pulmonary metastases, growing at identical and constant
rate. One of the metastases was irradiated (RT) once,
and the other twice. Both responded to the treatment,
but rapidly resumed growth after completion of therapy.
When growth was resumed, it was at a rate identical to
that in the pre-treatment period. Figure 10 depicts a case
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Figure 8. Growth rates for some pulmonary metastases.
Abscissa: Time.
Ordinate: number of tumor cells (logarithmic scale).
Each curve represents one case, and each point one observation.
Symbols: = leiomyosarcoma (Rööser et al [34])
= Ewing sarcoma (Pearlman [30])
= hypernephroma (Brenner et al [25])
The other three cases are metastases from colon carcinomas (Spratt & Spratt [23]). Four of the cases
display linearity of growth. Two cases of colon carcinoma show non-linearity. One case shows
acceleration, the other retardation of growth. All cases reproduced with the kind permission of the
editors.
Figure 9. Growth curves for two pulmonary metastases from a fibrosarcoma in one patient.
Abscissa: Time (in months).
Ordinate: Number of cells (logarithmic scale).
Each curve represents one metastasis, and each point one observation. RT= Radiation therapy. One of the metastases was
irradiated (=RT) once (II), and the other twice (I): the radiation doses were 37 and 50 Gray (Gy), respectively. The ikon in the top left
corner depicts the lungs, the localization of the metastases and the fields of irradiation. Copied and slightly modified from Breur [23].
Reproduced with the kind permission of the editor.
with two pulmonary metastases from a carcinoma of the
bladder.
Re l a t i o n  b e t w e e n  t h e  g r o w t h  r a t e s  o f  t h e
p r i m a r y  t u m o r  a n d  i t s  m e t a s t a s e s
Secondary tumors may grow at a different rate from that
of the primary tumor. There is a widespread belief that
metastases grow at rates faster than their primaries
through a selection of more aggressive clones. There is
very little support to this belief in the medical literature. It
cannot be excluded that this is based on the incorrect
plotting of the growth rates on an arithmetic scale (as
in Figure 1A) and not a semilogarithmic scale (as in
Figure 1B).
For example, Spratt [93]. studying 3 cases with
osteogenic sarcomas, found that the secondary tumors
in the lungs were similar or slower in growth rate than the
primary tumors in the same patient, but the observed
differences were not large. Breur [23] made the same
observation in a case with a sarcoma. Fujimoto et al [51]
studied 18 cases with renal cell carcinoma. The TVDT
of the 6 primary tumors ranged from 372 to 579 days
(468±43.0). The TVDT of the 12 pulmonary metastases
ranged from 20 to 154 days (89.4±43.0). It should be
noted, however, that the patients in whom the primary
tumors were measured were not the same patients in
whom the metastases were measured. The TVDT of the
primary tumors were exceptionally long (>1 year). The
reason cannot be that the tumors were measured during
the decelerating asymptotic phase: all tumors were less
than 5 cm in diameter, which is well below the asymptotic
level in Figure 2.
MacDonald [94] observed that the pulmonary
metastases from cancer of the breast grew somewhat
faster than the primary tumor. Tubiana et al [95], studying
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Table IV. Growth rates of pulmonary metastases divided according
to the site of the primary tumor
Primary TVDT (days) Numer Reference
of cases
Testis* 15 8 Breur [23]
” 3 5 Demicheli [49]
” 19 6 Collins [16]
” 43 13 Spratt [21]
Malignant melanoma 48 10 Knutsson [87]
(cuteaneous)
Malignant melanoma 35 18 Schötterl [88]
(ocular)
“ 49 18 Plesnicar [89]
“ 63 37 Eskelin [80]
Thyroid
anaplastic 29 4 Combes [90]
follicular 148 7 Combes [90]
Breast 82 29 Spratt [21]
” 83 6 Combes [90]
” 199 6 Breur [23]
Colon 106 14 Combes [90]
” 109 10 Spratt [23]
” 116 25 Collins [16]
Kidney 66 5 Chahinian [71]
” 89 12 Fujimoto [51]
” 132 8 Brenner [25]
Cervical uteri 89 5 Combes [90]
Mesenchymal† 8 – 198 11 Rööser [34]
” 11 – 120 15 Band [91]
” 3.9 – 352 21 Blomqvist [35]
” 5 – 200 25 Pearlman [30]
” 5 – 340 23 Spratt [21]
” 13 – 257 38 Breur [23]
” 5 – 360 64 Joseph [92]
* = NSGCT (Non-Semitomatous Germ Cell Tumors)
† = Various sites. Most cases were stated to be high-grade malignant.
The inter-individual variations in TVDT are so great that the range is
given rather than the mean
Figure 10. Growth curves for two pulmonary metastases from a case with bladder carcinoma.
All explanations, abbreviations and comments are as in Figure 8. Radiation dose was 56 Gy.
Copied and slightly modified from Breur [23]. Reproduced with the kind permission of the editor.
cancer of the breast, noted a TVDT of 105 days for the
primary tumor, and 66 days for the pulmonary metastases.
Kusama et al [52], studying 34 cases with cancer of
the breast, noted that the TVDT for the primary tumor
did not differ significantly from the TVDT of metastases
to the lungs or the lymph nodes in the same individual. If
the primary tumor grew fast, then the secondaries also
grew fast. Conversely, if the primary tumor grew slowly,
then the metastases grew slowly as well. von Fournier et al
[96], studying the same type of malignancy, made the
same observation in 16 cases with untreated breast cancer
and simultaneous measurements of their metastases to
the lungs. The impression from these studies is that the
growth rates of the metastases are similar to those of the
primary tumors.
If linear growth curves are constructed from the
values for TVDT in Tables I, II and IV, and based on the
assumption of a close relationship between the growth
rates of the primary tumors and their metastases, the
diagram in Figure 11 can be constructed. In this diagram,
the growth rates for testicular cancers and sarcomas are
taken from Table IV. The slope of the line in Figure 11 for
sarcomas is based on the mean of all observations of
TVDT of the various types. This is an obvious
oversimplification. The range of the TVDT for the 197
mesenchymal tumors in Table IV varies from 3.9 days to
360 days. Consequently, the time period from the first
tumor cell to reach detection level varies from 117 days to
some 30 years. The growth rate for epidermoid carci-
nomas of the lung is calculated from the mean value in
Table II. The growth rate for cancer of the breast is the
estimated median value from Table I.
Fast-growing tumors (acute leukemias, non-semino-
matous testicular tumors, anaplastic thyroid carcinomas
and some pediatric tumors) will “surface” in a year or
two. Slow-growing tumors (breast, prostate, colon and
several others) will require several years or even decades
to reach detection level.
W h e n  d o  c a n c e r s  s t a r t  t o  m e t a s t a s i s e ?
In humans, it is impossible to obtain experimental
evidence to answer this question. However, by measuring
the TVDT of metastases, and extrapolating back to one
cell, an approximation of the time of dissemination can be
obtained. 10 investigators have made attempts at
calculating the start of dissemination. The first of these
are summarized by Davies in 1977 [97]. Collins et al [15]
concluded from their studies on 23 cases with pulmonary
metastases from various primary tumors: "...the esta-
blishment of pulmonary metastases was earlier than the
first symptoms of the primary lesion in all but one of the
23 cases studied. "
Tubiana et al [95], studying cancer of the breast,
concluded that "50% of the metastases started to grow
two years before the detection of the primary tumor."
von Fournier et al [96] were able to measure both
the primary tumor and multiple metastases to the lung
from seven cases of carcinoma of the breast. By
backwards extrapolation, they concluded that "metastases
start their growth many years before the diagnosis of the
primary tumor". These authors also imply that already
after 21 doublings, (≈0,6 mm in diameter) tumors have
the ability to generate metastatic cells.
Bauer et al [98] concluded that for women with
axillary lymph-node metastases from the primary in the
breast, 90% of the metastases started to grow when the
primary was less than 6 mm in diameter. They based their
conclusion on a study of 337 cases. They end their sum-
mary: "The earliest diagnosis, taking technical possibilities
into account, can not be early enough to precede
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Figure 11. Hypothetical growth rates for various malignant human tumors.
Abscissa: Time (years).
Ordinate: Tumor size (log number of cells or weight of tumor).
The level of detection is indicated by the shaded area.
lymphatic spread." Breur [23] studied the growth rates
of various malignant human tumors. In 76 of his 86 cases,
the pulmonary metastases "originated well before the
treatment of the primary tumor, and in most cases before
the first symptoms were detected."
Rööser et al [34] studied l1 cases with pulmonary
metastases from soft tissue sarcoma. "In all but one case
microscopic pulmonary spread was calculated to be
present when the primary tumor was diagnosed."
All of the ten studies cited above have come to
similar conclusions: in the majority of cases (>75%) the
metastases started to grow years before the primary tumor
was even detected. In many of these cases the primary
had been removed, and there were no signs of local
recurrence, even at autopsy. The metastases must
therefore have been deposited before the removal of the
primary. Eskelin et al [80], in their study of pulmonary
metastases from ocular malignant melanomas, calculated
the secondaries to precede the diagnosis of the primary by
5 years. Schötterl and Paul [88] came to the same con-
clusion in their study of pulmonary metastases from
cutaneous malignant melanomas, as did Umeda et al [82]
for acinic cell carcinomas. Umeda’s et al growth curves
can explain why metastases from this type of cancer can
occur as much as 20 years after the removal of the
primary tumor.
The impression obtained from these ten studies can
not be valid for all types of human tumors, because local
therapy (surgery and/or radiotherapy) is still a curative
treatment for the majority of patients where permanent
cure really is achieved.
The present author is fully aware of the fact that
many tumors do not give rise to metastases until late in
their life span. Such tumors have usually not been repor-
ted in the literature, since they do not offer any possibility
of studying the growth rates of their secondary tumors.
The extremes of biological behavior of malignant tumors
range from rapidly metastasizing tumors which begin to
disseminate from the start, to tumors that never give rise
to visible metastases, no matter how large the primary
tumor grows.
S u p p o r t  f o r  t h e  c o n c e p t  o f  c o n s t a n t
g r o w t h  r a t e :  p e r i o d  o f  r i s k
Perhaps the strongest biological support for the assump-
tion of constant growth rate has been in the area of
malignant tumors in infants and children. Wilms’ tumor,
as an example, may be present at birth or appear within
the first months of life. Collins [16, 99] reasoned that if
a tumor were found in a 3-month-old infant, the
maximum age of the tumor from the single cell stage
would be the host’s age plus 9 months (gestation). If
recurrence or metastases should occur after resection,
and start regrowth from the minimum of one single cell,
then the tumor would reach diagnostic size within the
same period. In this case, at 15 months of age. Collins
was able to test his hypothesis in 340 cases. Of 75 children
who had passed the period of risk, 73 remained free of
disease.
In a similar study, Pollock et al [32] examined 95
patients with Wilms’ tumor and 68 patients with neuro-
blastoma. They found one single exception to Collins’
period of risk.
Knox and Pillers [100] examined 87 cases with
Wilms’ tumor, 126 cases with neuroblastoma, and 31 cases
with rhabdomyosarcoma. Among the 244 cases, all 192
recurrencies appeared within the period of risk. In total,
only 3 (0.6%) exceptions to Collins’ rule of the period of
risk were found in the first 482 cases studied. Not all
pediatric tumors follow Collins’ rule: astroglial tumors
seem to be an exception [101]. In a review by Brown et al
[102], the authors identified only 38 (0.17%) exceptions
from 2,233 non-astroglial pediatric cases. These results
give strong support to the concept of constant growth
rates.
It may be argued that pediatric tumors differ in their
behaviour from adult tumors. However, support for the
assumption of constant growth rate comes also from
studies of cancer of the breast in adults. Allan [103],
presented data from "late" recurrencies (over 5 years) of
cancer of the breast in 139 cases. He found a close
correlation between the latent period (up to more than 20
years) and the survival time (>10 years) after the "late"
recurrence. Allan’s cases would correspond to the 3 or 4
most slow-growing cases in Figure 4. He concluded that
there is "no justification for the concept of a dormant
state during the latent interval, and that the results are
consistent with the theory of constant growth rate of the
tumours".
Only tumors with a TVDT of less than 60 days can
be calculated to recur within 5 years if stemming from
one single cell at the time of removal of the primary
tumor (30 generations x 60 days = 1,800 days ≈ 5 years).
Of the more than 800 cases of cancer of the breast
summarized in Table I, only around 15% have a TVDT of
less than 60 days.
Recurrences appearing within 5 years after removal
of the primary can be explained in two ways: 1. they grow
faster than the primary tumor, or 2. they grow at the same
rate as the primary tumor, but they started to grow before
removal of the primary tumor.
The period of risk for the 12 cancers in Figure 4 can
be calculated to vary from a minimum of 9 years
(a TVDT of 88 days) to a maximum of over 50 years
(a TVDT of 512 days). A patient with such a slow-growing
tumor is likely to die with, but not from, her cancer
(= “personal cure”). Such a long period of risk is con-
sistent with the observed excess mortality from cancer of
the breast more than 30 years after the primary treatment
[104-108].
NSGCT (non-seminomatous germ cell tumors) have
a TVDT of around 20 days (Table IV). With such a short
doubling time the tumor will kill its host in a year or two.
This means that recurrences of testicular carcinomas
many years after the primary treatment are more likely to
be new malignancies than late recurrencies [109].
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Discussion
The facts given in this review are not new. Furthermore,
they are well documented: since the original studies by
Collins et al 40 years ago, almost 100 articles, seven
reviews [17, 40, 47, 68, 97, 110, 111,] and two books [40,
112] have been published on the topic. Yet, the con-
clusions from biological data are not always drawn in
extenso, and the medical and legal implications are
usually not taken fully into consideration. The practical
medical conclusions which can be drawn from Figure 11
can be extended, as illustrated in Figure 12.
In Figure 12 it is demonstrated that when a malig-
nant tumor can be detected by present-day diagnostic
methods it has consumed more than half of its life span, if
left alone or unaffected by treatment. A total tumor
burden of 1012 (≈ 1 kg) in children, to 1013 cells (≈ 10 kg
or around the 45th tumor cell generation) for an adult
individual may be regarded as lethal (10% of the body
weight). This level seems to be valid for both solid tumors
and haematological malignancies [7, 17, 18, 21, 29, 48,
113]. If the TVDT of the primary tumor is known,
antegrade extrapolation – Figure 12 – can therefore
be used for prognostication. For example, a patient
with a malignant tumor with a TVDT of 10 days has
a maximum of 450 days from the first tumor cell to
survive if untreated.
However, the lifespan of that patient ought to be
shorter, since the metastases (and their secondaries) will
contribute to the total tumor burden of the host.
Recurrences from testicular carcinomas, which are fast
growing tumors, hardly ever occur later than 24 months
after treatment of the primary [114]. In contrast, a patient
with a slow-growing cancer of the breast or the prostate,
can be expected to have around 5 years to survive from
the detection level, even if untreated.
W h i c h  p a t i e n t s  w i l l  b e n e f i t  f r o m  
s o - c a l l e d  “ e a r l y  d i a g n o s i s ” ?
Some patients actually do benefit from “early diagnosis”
(the term is never properly defined), and this is illustrated
in Figure 13. As can be seen from this figure, the three
most rapidly growing cancers (A, B, and C) have given
rise to metastases before the new diagnostic level is
reached. These patients will not benefit from “earlier”
diagnosis.
The two most slow-growing tumors will start to
metastasise late, and after the old diagnostic level has
been passed by the primary (tumors H and J). These
patients will not benefit from the new diagnostic method
since the tumor can be detected by the old method. The
only patients who will benefit from “early” diagnosis are
those whose tumors start to disseminate in the interval
between the two diagnostic levels (tumors D – G); in this
example 1/3 of the tumors.
This illustrates why a new screening method will not
be of benefit to all patients. For cancers of the breast
(in plural!), Figure 13 could explain why 1/3 of the
patients have metastases to the bone marrow already at
the time of diagnosis, according to Braun et al [115].
Local therapy cannot affect the outcome of a generalized
malignancy.
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Figure 12. "Period of risk" for two human malignant tumors.
To the left (A): a hypothetical line for a malignant tumor with a TDVT of 10 days.
To the right (B): the corresponding line for a tumor with a TVDT of 150 days.
Both tumors are assumed to be untreated. In the diagram, the total tumor burden (1 – 10 kg) is assumed to be provided by the primary tumor plus its
metastases. The period of risk is defined as the period beginning with removal of the primary just prior to reaching the lethal burden, and recurrence
stemming from one single cell, growing at a rate similar to the primary tumor and starting when the primary tumor was removed. The period ends when
the recurrent cell population has reached the lethal burden.
T h e  5 - y e a r  s u r v i v a l  r a t e :  p a r t i a l l y
a m y t h ?
For long, the cliché “early diagnosis leads to better
prognosis” has echoed in the medical world. But to a large
extent it is a myth, based on a misunderstanding which is
termed “lead time bias”. The term is best explained by an
illustration (Figure 14).
The term “lead time bias” was introduced already in
the 1960’s [116]. If the lead time is not corrected for, the
outcome of several clinical trials will be misinterpreted.
This mental trap was pointed out already in the 1940’s by
statisticians [117], by the legal profession (since this trap
is of profound importance in malpractice claims) [118,
119], but only occasionally by the medical profession.
The 5-year survival rate has for a long time been
used as an index of the effectiveness of the treatment for
cancer. It has been widely used since the end of the 19th
century, and thousands of scientific publications have
utilized it. Basically, the 5 year survival rate is a statistical
tool for characterizing the survival of a certain group of
individuals. It is somewhat primitive, since it does not
utilize all available information from a survival analysis. It
only tells how large a proportion has survived for a limited
time span – arbitrarily put to 5 years. It is not even a true
rate, but simply a value at a fixed point of time [120, 121].
The 5-year survival can even be misleading: It is easy
to give examples of quite different survival patterns with
identical five-year survival rates (Figure 15). However, if
the original intention with the “five-year survival” had
been maintained – as a mere value in time – then no
harm would have been done. But over the years a change
has occurred in the meaning (interpretation?) of the term
“five-year survival rate”. It has gradually shifted to
become the equivalent to “five-year-cure rate”. This is
a gross misconception because “survival” is not syno-
nymous with “cure”. It is only for fast-growing tumors
(e.g. acute leukemias and testicular non-seminomatous
germ cell tumors) that surviving for five years after the
diagnosis is likely to indicate a true cure. This is illustrated
by curve B in Figure 15. Most human malignancies,
however, are slow-growing, (i.e. most cancers of the
breast, colon or prostate) and require many years or even
decades to kill their host. For such cases, survival for five
years is not indicative of cure. For example, of the women
who survive their breast cancer diagnosis for five years, 1/3
will succumb to their disease, and for those women who
have survived for 10 years, as much as 1/4 will still die
from their malignancy. Even as long as 30 years after the
diagnosis, this patient population shows an over-mortality
from cancer of the breast. Consequently, some clinicians
have posed the question: “Do we ever cure cancer of the
breast?” (For summary, see ref 107). The cliché “earlier
diagnosis leads to better prognosis” and the miscon-
ception “five-year cure” have done more harm than good.
The cliché lacks firm scientific support, and the words
“early” and “cure” are often used without being defined.
If “early” is supposed to mean “before the tumor has
metastasised”, this is another illusion: most human tumors
have metastasised when diagnosable by present-day
methods, as summarized in this article. Further, the word
“cure” should be used with caution. Many adult malignant
tumors have a long natural course extending over two or
three decades. This means that there are many individuals
who, after having had thir primary tumors removed, live
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Figure 13. Time for first metastasis for a hypothetical group of tumors.
Ordinate: Time.
Abscissa: Size of tumor.
Each curve represents one tumor growing at constant rate.
On each curve there is an X, indicating time for first metastasis. The slower the growth rate, the later the
tumor starts to give rise to metastases. In this figure, the two levels indicate the old and the new, more
sensitive level of detection, respectively.
with asymptomatic, microscopic disease (like many other
chronic diseases). These patients have not been cured,
but they live seemingly healthy with “no evidence of
disease”.
In clinical oncology a wholly satisfactory definition of
the term “cure” is therefore regarded as difficult – if not
impossible [122]. There are three current definitions of
cure: 1. statistical, 2. clinical, and 3. personal. “Statistical
cure” means that the study population dies at the same
rate as the “normal” population (regardless of diagnosis).
“Clinical cure” designates the situation in which the study
population dies of its malignancy at the same rate as the
“normal” population (with the same diagnosis). “Personal
cure” means that the study population dies w i t h  its
disease, but not f r o m  it (i.e. death from a cardiovascular
disease, but with known active tumor). It is a paradox
that whatever definition of “cure” is chosen, the patient
must die – and be autopsied – before he or she can be
declared healthy. This is of particular importance in
clinical trials [123].
Thus – regardless of which of these definitions is
intended – a five-year survival period should not be
equated with “cure” for most malignancies. In spite of
this, the “five-year cure rate” has been hammered into the
heads of the public, the medical profession, the
journalists, the legal profession, and many others, for so
long that it has become an axiom. It is written in the
minds of the people, in publications and in text-books.
Nevertheless, we tend to hold fast to the clichés of
our teachers, enjoying the comfort of popular opinion,
simultaneously avoiding the discomfort of thought.
If a false statement (i.e. surviving for five years
means cure) is repeated sufficiently often, it will be
accepted as a truth. It is noteworthy that clearsighted
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Figure 14. “Lead time bias”.
Ordinate: Time.
Abscissa: Amount of disease.
The straight line depicts the evolution of a lethal disease, starting at origo and killing its host at the
level of the arrow. The disease must not necessarily be a malignant tumor; it can be any lethal
disease with a protracted course (amyotrophic lateral sclerosis, AIDS, Parkinson’s disease, etc.). The
outcome for two groups of patients is followed for 5 years. In group A observation starts “early”.
After 5 years (the lower of the two horizontal bars), the number of deaths amounts to zero. In the
“late” group (B), 50% of the patients are dead after 5 years. The obvious conclusion is that “early”
detection leads to better prognosis, which is an illusion. Shifting the time of diagnosis to an earlier
date will only provide longer observation time. Disease specific mortality, however, will not be
affected.
Figure 15. Two series with identical five year survival rates (50%).
Survival in series A is better for the first four years, but practically nil
after seven years. Survivor in series B can be regarded as cured after
three years.
criticism of the medical clichés, terms and misconceptions
does not come from a profession with a medical edu-
cation, but from one without such an education: the legal
profession [118, 119].
The illusion created by the five-year cure rate gives
false promises based on false premises: bitter frustration
among patients (who experience recurrences and/or
metastasis 10 or 15 years after the first five-year period),
confusion and denial in the medical profession and law
suits against doctors [124, 125]. The delayed diagnosis of
breast cancer is now the most frequent medical
malpractice claim in the United States, and “it is the
second most expensive condition for insurers to
indemnify” [125].
In Figure 16, the evolution of one and the same
tumor detected on two different occasions is illustrated.
The two growth curves are linked with a 5-year
observation period for the prognosis. This is a somewhat
complicated attempt to combine growth curves of tumors
with the pit-fall “lead time bias”, trying to explain why
the cliché “early detection leads to better prognosis” to
a large extent is a myth. The numerical comparison
between the two situations for the same tumor is
condensed in Table V (which is inserted in Figure 16),
where the size of the primary tumor, the number of
metastases d e t e c t e d  (which is not the same as the
number of metastases e x i s t i n g) and the 5-year survivals
are compared. The obvious conclusion from Table V is
that “early detection leads to better prognosis” if the
survival figures are compared. However, this conclusion is
erroneous: If the observation period is not truncated at 5
years but extended to 7 years, the prognosis is identical for
the two situations. This is an illustration of how myths
and illusions are created.
If we are to make any progress in the war against
cancer, we must first recognize the limitations set by
nature [126, 127].
Conclusions
Knowledge of the above facts is important for several
reasons. First, the value of so-called "early" diagnosis has
become questionable. The word "early" is not even
defined in most publications. Whatever definition is used,
the word "early" can be regarded as a misnomer when
used to describe a tumor that is actually 5 or 10 years of
age when detected. Screening the healthy population for
malignant tumors – be it cancer of the breast by
mammography or cancer of the prostate by measurement
of PSA – may therefore not reduce the mortality from
these diseases as much as expected. Already in 1951,
McKinnon [128] titled an article: "The invalid evidence for
faith in early treatment." So-called "early" detection is in
fact "biologically late", as stated by MacDonald in 1966
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Figure 16. “Lead time bias”, graphically and numerically illustrated.
Abscissa: Time.
Ordinate: Size of tumor.
The detection level and the lethal burden are indicated.
P = primary. M = metastases. → = 5 years.
The graph shows the same tumor on two different occasions. In situation A, the primary tumors is
detected at a size of 1 cm in diameter, and no metastases are found (although they exist). The 5-year
survival is 95%. In situation B, the primary tumor is 2 cm’s in diameter, 2 metastases are found and
the 5-year survival is 70%. Note that in situation A there are as many metastases as in situation B, but
none of those in A are detected. Table V is a numerical presentation of the curves depicted. If the
observation time is not truncated after 5 years but extended to 7 years, then all patients will have
died. No survival benefit for situation A (“early detection”) would remain.
[94]. The most common mistake is to regard a small
tumor as an "early" tumor. This is not so: when
a malignant tumor is detected, it has already existed for at
least half of its life-span. This may explain why mammo-
graphy has not been able to reduce mortality from cancer
of the breast as much as initially expected. The number of
women screened to achieve one less death per year ranges
from 7,068 in one study to 63 264 in another study to
infinity in a third [129].
A recent meta-analysis from the Cochrane Institute
based on the six largest mammography trials concludes:
“Mammography is not justifiable” [130]. The mere fact
that 40 years after the introduction of mammography we
are still discussing its possible benefits; an indication as
good as any of its questionable value. To give another
example, screening for lung cancer in order to obtain
“early” detection has not reduced mortality from these
diseases [131]. Screening for lung cancer is therefore
advised against [132].
Second, knowledge of human tumor kinetics may
influence the outcome of legal trials in which the possible
influence of patients’ or doctors’ delays on the prognosis
of the patient is at stake. The importance of ”early”
detection of tumors for the prognosis of the patient has
been grossly overestimated, because clinically detectable
tumors are not early. Dissemination may have occured
long before the diagnosis of the primary tumor.
Moreover, a delay of one or two months in the
diagnosis of a slow-growing malignant tumor – such as
cancer of the breast – will amount to 1 or 2% of the total
consumed life-span of that tumor. Displacing the
diagnosis to an earlier date will prolong the observation
period without influencing the time of death for a non-
treated patient. If the diagnostic level of an untreated
tumor with a TVDT of 150 days was shifted from 1 cm
diameter (≈109 cells) to a 2 mm in diameter (≈107 cells),
this would increase the observation time with almost 3
years ”lead time”. Such patients will live longer as cancer
cases, but not as individuals. The medico-legal problem of
malpractice claims for doctor’s delay is increasing, but
has so far received but little attention in the medical
literature. One notable exception is the article by Spratt
and Spratt [133].
”Early” therapy of a primary tumor will lead to
a reduction in mortality, only if the primary tumor can be
eliminated before dissemination begins. And, as is shown
in this review, dissemination frequently begins prior to
the detection of the primary tumor. In such cases, local
treatment of the primary tumor will not prevent
dissemination. Nor will local treatment improve the long-
term prognosis of the patient. This emphasizes the need
for better generalized treatment, not the need for better
diagnostic methods or better local treatment of the
primary. Whatever type of surgery for cancer of the breast
is used, it does not affect survival. Local treatment
cannot affect metastases. In contrast, when generalized
malignancies are cured – like some leukemias or testicular
tumors – it is not because they are detected early, but
because the tumor cells are susceptible to treatment.
But there are examples where “early” detection
really results in a decrease of mortality: malignant mela-
noma of the skin, cervical cancer of the uterus, and cancer
of the breast. These three malignancies share two cha-
racteristics. First, they have a long pre-clinical phase in the
form of pre-cursor lesions: dysplastic naevi, cancer in situ
and ductal cancer in situ (DCIS), respectively. Second,
they can relatively easily be detected: the first two by the
eye, and the latter with mammography. If removed while
still in the pre-cursor phase before they are invasive,
mortality from these three malignancies will be reduced.
Third, the design and analysis of clinical trials may be
affected by knowledge of tumor kinetics [123]. If cancer
specific death is used as an end-point in individual cases,
then that point will be reached in a few years for fast-
growing tumors (curve B in Figure 15). For slow-growing
malignancies, in contrast, a 5- or 10-year observation
period may not even cover the natural course of the
disease. For cancer of the breast, the prostate and the
kidney, for example, the excess mortality from the
diseases remains as long as 20 years after the primary
treatment [107]. The long-term survival curves from
cancer of the breast and renal cell cancer [134] are
particularly striking. Moreover, if the TVDT is not taken
into consideration, an uncritical interpretation of survival
curves may be misleading [120]. For example, survival
curves from patients with one clinical stage may not be
directly compared to patients with another clinical stage
of a similar tumor, because the two groups of patients
are at different levels on the growth curve when the
observation starts (Figure 16).
The two groups of patients may also represent
different types of malignancies originating in the same
organ, but lumped together under the same diagnosis.
The wide range of growth rates for cancer of the breast
illustrated in Figure 4 may also reflect highly variable
biological properties, like metastasizing potential. It is
possible that "stage II breast cancer is not simply a late
stage I", as stated by Mueller [135].
Fourth, interpretation of some epidemiological data
may be reconsidered. If a tumor reaches the diagnostic
level when it is 10 years old, it is not likely to have been
initiated by a suspected carcinogen to which the patient
was exposed only 5 years earlier. The causative agent
must be searched for more than 10 years before the
diagnosis.
Fifth, as stated above, insurance policies may be
affected by awareness of tumor kinetics. There is ample
evidence that metastases progress at roughly the same
rate (= similar TVDTs) as the primary tumor. Therefore,
if 12 years are required for the primary tumor to reach
a size of 1 cubic centimetre, it is likely that some of the
secondaries will need the same period of time to reach
detectable levels. Some “late recurrencies” or so-called
“dormant cells” – appearing decades after removal of the
primary – may be neither late nor dormant. They may
simply reflect the natural history of a slow-growing
neoplasm. For slow-growing cancers – and many cancers
of the breast, prostate, colon and kidney belong to this
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category – these facts lead to the conclusion that the 5-
year survival rate is no reliable measure of cure [120,
121].
However, if the TVDT of a tumor is known, “the
period of risk” can be estimated relatively accurately.
The use of TVDT as a yardstick of survival is a more
realistic measure of treatment efficacy than arbitrary units
of time. If the TVDT – and hence the period of risk – is
doubled by treatment, this may be a more appropriate
measure of treatment efficacy than an increase in the
number of 5-year survivors. A host having pulmonary
metastasis 20 mm in diameter has a 95% probability of
dying within 11 more tumor doublings [20]. The duration
of his life, however, may vary from some 100 days with
a TVDT of 10 days to 2, 160 days (≈6 years) with a TVDT
of 200 days. This, in turn, may have implications for
insurance companies and their risk estimations.
Sten Friberg MD, PhD
Banérgatan 21, VII
SE-115 22 Stockholm
Sweden
References
1. Friberg S, Mattson S. On the growth rates of human malignant tumors:
Implications for medical decision making. J Surg Oncol 1997; 65: 
284-97.
2. Holmgren L, O’ Reilly M, Folkman J. Dormancy of micrometastases:
Balanced proliferation and apoptosis in the presence of angiogenesis
suppression. Nature Medicine 1995; 1: 149-53.
3. Virchow R. “Vorlesungen über Pathologie”. Berlin: A Hirchwald Verlag,
1862, p 1.
4. Waldenström J. Hypergammaglobulinemia as a clinical hematologic
problem: A study in the gammopathies. Progr Haemotol 1962; 3: 266-93.
5. Fialkow PJ. The origin and development of human tumors studied with
cell markers. N Engl J Med 1974; 291: 26-34.
6. Hobbs JR. Growth rates and responses to treatment in human
myelomatosis. Brit J Haemat 1969; 16: 607-17.
7. Hobbs J. Immunocytoma o’ mice an’ men. Br Med J 1971; 2: 67-72.
8. Gilliland DG, Blanchard KL, Levy J et al. Clonality in myeloproliferative
disorders: Analysis by means of the polymerase chain reaction. Proc Natl
Acad Sci USA 1991; 88: 6848-52.
9. Sidransky DS, Frost P, von Eschenbach A et al. Clonal origin of bladder
cancer. N Engl J Med 1991; 326: 737-40.
10. Noguchi S, Aihara T, Koyama H et al. Discrimination between
multicentric and multifocal carcinomas of the breast through clonal
analysis. Cancer 1994; 74: 872-77.
11. Wang N, Perkins KL, Bronson DL et al. Cytogenetic evidence for
premeiotic transformation of human testicular cancers. Cancer Res 1981;
41: 2135-40.
12. Skakkebaekk NE, Berthelsen JU, Giwercman A et al. Carcinoma-in-situ
of the testis: possible origin from gonocytes and precursors of all types
of germ cell tumors except spermatocytoma. Int J Urol Androl 1987; 10: 
19-28.
13. Chaganti RSK, Rodriguez E, Mathew S. Origin of adult male mediastinal
germ-cell tumors. Lancet 1994; 343: 1130-2.
14. Steel GG. Cell loss as a factor in the growth rate of human tumours. Eur
J Cancer 1967; 3: 381-7.
15. Refsum SB, Berdal P. Cell loss in malignant tumours in man. (Letter to
Editor). Eur J Cancer 1967; 3: 235-236.
16. Collins VP, Loeffler RK, Tivey H: Observations on growth rates of human
tumors. Am J Roentgen 1956; 76: 988-1000.
17. Schwartz M. A biomathematical approach to clinical tumor growth.
Cancer 1961; 14: 1271-94.
18. Spratt JS, Ter-Pogossian M, Long RTL. The detection and growth of
intrathoracic neoplasms. Arch Surg 1963; 86: 283-8.
19. Garland LH, Coulson W, Wollin E. The rate of growth and apparent
duration of untreated primary bronchial carcinoma. Cancer 1963; 16:
694-707.
20. Spratt JS, Spjut HJ, Roper CL. The frequency distribution of the rates of
growth and the estimated duration of primary pulmonary carcinomas.
Cancer 1963; 16: 687-93.
21. Spratt JS, Spratt TL: Rates of growth of pulmonary metastases and host
survival. Ann Surg 1964; 159: 161-71.
22. Weiss W, Boucot KR, Cooper DA. Growth rate in the detection and
prognosis of bronchogenic carcinoma. JAMA 1966; 198: 108-14.
23. Breur K. Growth rate and radiosensitivity of human tumors – I. Eur
J Cancer 1966; 2: 157-71.
24. Breur K. Growth rate and radiosensitivity of human tumors – II. Eur
J Cancer 1966; 2: 173-188.
25. Brenner MW, Holsti LR, Perttala Y. The study by graphical analysis of the
growth of human tumours and metastases of the lung. Br J Cancer 1967;
21: 1-13.
26. Rambert PE, Malaise E, Laugier A et al. Donnés sur la vitesse de
croissance de tumours humaines. Bulletin du Cancer 1968; 55: 323-42.
27. Meyer JA The concept and significance of growth rates in human
pulmonary tumors. Am Thorac Surg 1972; 14: 309-22.
28. Steele JD, Buell P. Asymptomatic solitary pulmonary nodules. Host
survival, tumor size and growth rate. J Thorac Cardiovasc Surg 1973; 65:
140-51.
29. Pearlman AW. Growth rate investigation and tumor lethal dose in Ewing’s
sarcoma. Acta Radiol 1973; 12: 57-70.
30. Pearlman AW. Breast cancer: Influence of growth rate on prognosis and
treatment evaluation. Cancer 1976; 38: 1826-33.
31. Pearlman AW. Fibrosarcaoma: The biomathematical approach to late
metastases – a case report. Mount Sinai J Med 1979; 46: 255-60.
32. Pollock WF, Hastings N, Snyder WH. The Collins “period of risk” formula
for malignant tumors in children, with particular reference to Wilms’
tumor and neuroblastoma. Surgery 1960; 48: 606-9.
33. Fournier D v, Weber E, Hoeffken W et al. Growth rate of 147 mammary
carcinomas. Cancer 1980; 45: 2198-207.
34. Rööser B, Petterson H, Alvegˆrd T. Growth rate of pulmonary metastases
from soft tissue sarcoma. Acta Oncol 1987; 26:189-92.
35. Blomqvist C. Wiklund T, Tarkkanen M et al. Measurement of growth
rate of lung metastases in 21 patients with bone or soft-tissue sarcoma. Brit
J Cancer 1993; 68: 414-7.
36. Gompertz B. On the nature of the function expressive of the law of
human mortality, and on a new mode of determining the value of life
contingencies. Phil Trans Roy Soc London 1825; 115: 513-83.
37. Winsor CP. The Gompertz curve as a growth curve. Proc Nat Acad Sci
1932; 18: 1-8.
38. Steel GG, Lamerton LF. The growth rate of human tumours. Br J Cancer
1966; 20: 74-86.
39. Dethlefsen LA, Prewitt JMS, Mendelsohn ML. Analysis of tumor growth
curves. J Natl Cancer Inst 1968; 40: 389-405.
40. Steel GG. Growth Kinetics of Tumours: Cell Population Kinetics in Relation
to the Growth and Treatment of Cancer. Oxford: Clarendon Press; 1977.
41. Plevritis SK. A mathematical algorithm that computes breast cancer sizes
and doubling times detected by screening. Mathematical Biosciences 2001;
171: 155-78.
42. van Leeuwen IMM, Zonneveld C, Kooijman SALM. The embedded
tumour: host physiology is important for the evaluation of tumour growth.
Brit J Cancer 2003; 89: 2254-63.
43. Kopans PB, Rafferty E, Georgian-Smith D et al. A simple model of
breast carcinoma growth may provide explanations for observations of
apparently complex phenomena. Cancer 2003; 97: 2951-9.
44. Stamey TA, Kabalin JN, McNEal JE et al. Prostate specific antigen in the
diagnosis and treatment of adenocarcinoma of the prostate II. Radical
prostatectomy treated patients. J Urol 1989; 141: 1076-83.
45. Spratt JS, Greenberg RA, Heuser LS. Geometry, growth rates and
duration of cancer and carcinoma in situ of the breast before detection by
screening. Cancer Res 1986; 46: 970-4.
46. Yankelevitz DF, Kostis WJ, Hensche CI et al. Overdiagnosis in chest
radiographic screening for lung carcinoma – Frequency. Cancer 2003;
97: 1271-5.
47. Shackney SE, McCormack GW, Cuchural GJ. Growth rate patterns of
solid tumors and their relation to responsiveness to therapy. Ann Int Med
1978; 89: 107-21.
48. Frei E, Freireich EJ. Progress and perspectives in the chemotherapy of
acute leukaemia. Adv Chemother 1965; 2: 269-98.
49. Demicheli R. Growth of testicular neoplasm lung metastases: Tumor-
specific relation between two Gompertzian parameters. Eur J Cancer
1980; 16: 1603-8.
20
50. Spratt JS, Ackerman LV. The growth of a colonic adenocarcinoma. Am
Surg 1961; 27: 23-8.
51. Fujimoto N, Sugita A, Terasawa Y et al. Observations on the growth rate
of renal cell carcinoma. Int J Urol 1995; 2: 71-6.
52. Kusama S, Spratt JS, Donegan WL et al. The gross rates of growth of
human mammary carcinoma. Cancer 1972; 30: 594-9.
53. Peer P, van Dijk J, Hendriks J et al. Age-dependent growth rate of primary
breast cancer. Cancer 1993; 71: 3547-51.
54. Kuroishi T, Tominaga S, Morimoto T et al. Tumor growth rate and
prognosis of breast cancer mainly by mass screening. Jpn J Cancer Res
1990; 81: 454-62.
55. Arnerlöv C, Emdin SO, Lundgren B et al. Breast carcinoma growth rate
described by mammographic doubling time and S-phase fraction. Cancer
1992; 70: 1928-34.
56. Ingleby H, Moore L, Gershon-Cohen J. A roentgenographic study of the
growth rate of 6 “early” cancers of the breast. Cancer 1958; 11: 726-30.
57. Ingleby H, Gershon-Cohen J. Comparative Anatomy, Pathology and
Roentgenology of the Breast. Philadelphia: University of Pennsylvania
Press; 1960.
58. Gershon-Cohen J, Berger SM, Klickstein HS. Roentgenography of breast
cancer moderating concept of “biologic predeterminism”. Cancer 1963; 16:
961-4.
59. Spratt JS, Kaltenbach ML, Spratt J. Cytokinetic definition of acute and
chronic breast cancer. Cancer Res 1977; 37: 226-30.
60. Lundgren B. Observations on growth rate of breast carcinomas and its
possible implications for lead time. Cancer 1977; 40: 1722-5.
61. Heuser L, Spratt JS, Polk HC. Growth rates of primary breast cancers.
Cancer 1979; 43: 1888-94.
62. Heuser L, Spratt JS, Polk HC et al. Relation between mammary cancer
growth kinetics and the interval between screenings. Cancer 1979; 43:
857-62.
63. Spratt JS, Chang AFC, Heuser LS et al. Acute carcinoma of the breast.
Surg Gynecol Obstet 1983; 157: 220-2.
64. Buchanan JB, Spratt JS, Heuser LS. Tumor growth, doubling times and
the inability of the radiobiologist to diagnose certain cancers. Radiol Clin
N Am 1983; 21: 115-26.
65. Heuser LS, Spratt JS, Kuhns JG et al. The association of pathologic and
mammographic characteristics of primary human breast cancers with
“slow” and “fast” growth rates and with axillary lymph node metastases.
Cancer 1984; 53: 96-98.
66. Spratt JS, Spratt JA. What is breast cancer doing before we can detect it?
J Surg Oncol 1985; 30: 156-60.
67. Galante E, Guzzon A, Gallus G, et al. Prognostic significance of the
growth rate of breast cancer: preliminary evaluation on the follow-up of
196 breast cancers. Tumori 1981;67:333-340.
68. Geddes DM. The natural history of lung cancer: a review based on rates
of tumour growth. Br J Chest Dis 1979; 73: 1-17.
69. Weiss W. Tumor doubling time and survival of men with bronchogenic
carcinoma. Chest 1974,65: 3-8.
70. Charbit A, Malaise EP, Tubiana M. Relation between the pathological
nature and growth rate of human tumors. Eur J Cancer 1971; 7: 307-15.
71. Chahinian P, Israel L. Survival gain and volume gain: Mathematical tools
in evaluating treatments. Eur J Cancer 1969; 5: 625-9.
72. Mattson K, Holsti LR. Prognostic value of doubling time in lung cancer.
Strahlentherapie 1980; 156: 632-6.
73. Brigham BA, Bunn PA, Minna JD et al. Growth rates of small cell
bronchogenic carcinomas. Cancer 1978; 42: 2880-6.
74. Hasegawa M, Sone S, Takashima S et al. Growth rate of small lung
cancers detected on mass CT screening. Brit J Radiol 2000; 73.1252-9.
75. Winer-Muram H, Jennings SG, Tarver RD et al. Volumetric growth rate
of stage I lung cancer prior to treatment: Serial CT scanning. Radiology
2003; 223: 798-805.
76. McLean IW, Foster WD, Zimmerman LE et al. Inferred natural history of
uveal melanoma. Invest Ophthalmol Vis Sci 1980; 19: 760-70.
77. Gass, JDM. Comparison of uveal melanoma growth rates with mitotic
index and mortality. Arch Ophtalmol 1985; 103: 924-31.
78. Manschot WA and van Strik R. Uveal melanoma: Therapeutic
consequences of doubling times and irradiation results; a review.
International Ophtalmology 1992; 16: 91-9.
79. Ollila DW, Stern SL, Morton DL. Tumor doubling time: A selection
factor for pulmonary resection metastatic melanoma. J Surg Oncol 1998;
69: 206-11.
80. Eskelin S, Pyrhönen S, Summanen P et al. Tumor doubling times in
metastatic malignant melanoma of the uvea. Ophtalmology 2000; 107:
1443-9.
81. Augsburger JJ, Gonder JR, Amsel J et al. Growth rates and doubling
times of posterior uveal melanomas. Ophthalmology 1984; 91: 1709-15.
82. Umeda M, Nishimatsu N, Masago H et al. Tumor-doubling time and
onset of pulmonary metastasis from adenoid carcinoma of the salivary
gland. Oral Surg Oral Med Oral Pathol Radiol Endod 1999; 88: 473-8.
83. El-Serag HB and Mason AC.Rising incidence of hepatocellular
carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
84. Kubota K et al. Growth rate of primary single hepatocellular carcinoma.
Determining optimal screening interval with contrast enhanced
computed tomography. Digestive Diseases and Sciences 2003; 48: 581-6.
85. Okazaki N et al. Evaluation of the prognosis for small hepatocellular
carcinoma based on tumor volume doubling time. A preliminary report.
Cancer 1989; 63: 2207-10.
86. Sheu JC et al. Growth rate of asymptomatic hepatocellular carcinoma
and clinical implications. Gastroenterology 1985; 89: 259-66.
87. Knutson CO et al. Melanoma. Review. Curr Probl Surg 1971; 12: 3-55.
88. Schötterl H-D and Paul E.Growth dynamics of malignant melanoma.
Tumor duplication time morphometrically measured in X-ray pictures of
pulmonary metastases. Zeitschrift für Hautkrankenheiten 1988; 63: 481-7.
89. Plesnicar S, Klanjscek G, Modic S: Actual doubling time values of
pulmonary metastases from malignant melanoma. Aust N Z J Surg 1978;
84: 23-5.
90. Combes PF, Douchez J, Carton M et al. Etude de la croissance des
métastases pulmonaires humaines comme argument objectif d’evaluation
du prognostic et des effets thérapiques. J Radiologie et d’Electrologie
1968; 49: 893-902.
91. Band PR, Kocandrle C. Growth rate of pulmonary metastases in human
sarcomas. Cancer 1975; 36: 471-4.
92. Joseph WL, Morton DL, Adkins PC. Prognostic significance of tumor
doubling time in evaluating operability in pulmonary metastatic disease.
J Thor Cardiovasc Surg 1971; 61: 23-32.
93. Spratt JS. The rates of growth of skeletal sarcomas. Cancer 1965; 18: 
14-24.
94. MacDonald JS. Radiological methods of measurement. In: Clinical
Evaluation of Breast Cancer. New York: Hayward & Bulbrock; 1966,
11-34.
95. Tubiana M, Chauvel P, Renaud A et al. Vitesse de croissance et histoire
naturelle du cancer du sein. Bulletin du Cancer 1975; 62: 341-58.
96. von Fournier D, Hoeffken W, Junkermann H et al. Growth rate of
primary mammary carcinoma and its metastases. In: Zander J, BaltzerJ
(eds). Early Breast Cancer. Berlin: Springer-Verlag; 1985.
97. Davies JNP. Overview of the biology and pathology of metastasis. In: Day
SB, Myers WPL, Stansly P et al (ed), Cancer Invasion and Metastasis:
Biologic Mechanisms and Therapy: Progress in Cancer Research and
Therapy. New York: Raven Press; 1977; 5: 15.
98. Bauer W, Igot JP, Le Gal Y. Chronologie du cancer mammaire utilisant
un mod¯le de croissance de Gompertz. Annales d’Anatomie Patologique
1980; 25: 39-56.
99. Collins VP. The treatment of Wilms`s tumor. Cancer 1958; 11: 89-94.
100. Knox WE, Pillers EMK. Time of recurrence or cure of tumours in
childhood. Lancet 1958; 188-91.
101. Austin EJ, Alvord EC. Recurrences of cerebellar astrocytomas:
A violation of Collins’ law. J Neurosurg 1988; 68: 41-7.
102. Brown WD, Tavaré CJ, Sobel EL et al. Medulloblastoma and Collins’
law: A critical review of the concept of a period of risk for tumor
recurrence and patient survival. Neurosurgery 1995; 36: 691-7.
103. Allan E. Breast cancer: The long latent interval. Eur J Cancer 1977; 13:
839-45.
104. Duncan W, Kerr GR. The curability of breast cancer. Br Med J 1976; 2:
781-3.
105. Rutqvist LE, Wallgren A, Nilsson B. Is breast cancer a curable disease?
Cancer 1984; 53: 1793-800.
106. Rutqvist LE, Wallgren A. Long-term survival of 458 young breast cancer
patients. Cancer 1985; 55: 658-65.
107. Joensuu H, Toikkanen S. Cured of breast cancer? J Clin Oncol 1995; 13:
62-9.
108. Cuzick J, Stewart H, Rutqvist LE et al. Cause-specific mortality in long-
term survivors of breast cancer who participated in trials of radiotherapy.
J Clin Oncol 1994; 12: 447-53.
109. Borge N, Fossˆ SD, Stenwig AE. Metastatic testicular cancer and
extragonadal germ cell tumor presenting with neurological symptoms.
J Neurooncol 1990; 8: 145-8.
110. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid
neoplasms: Part I. J Surg Oncol 1995; 60: 137-46.
111. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid
neoplasms: Part II. J Surg Oncol 1996; 61: 68-83.
112. Oeser H v. Krebsbekämpfung: Hoffnung und Realität. Stuttgart: Georg
Thieme Verlag; 1974.
113. Salmon SE, Smith BA. Immunoglobulin synthesis and total body tumor
cell number in IgG multiple myeloma. J Clin Invest 1970; 49: 1114-21.
21
114. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine
and bleomycin combination chemotherapy in disseminated testicular
cancer. Ann Int Med 1977; 87: 293-8.
115. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone
marrow and survival patients with stage I, II, or III breast cancer. N Engl
J Med 2000; 342: 525-33.
116. Hutchison GB, Shapiro S. Lead time gained by diagnostic screening
for breast cancer. J Nat Cancer Inst 1968; 41: 665-81.
117. Boag JW. Maximum likelihood estimates of the proportion of patients
cured by cancer therapy. J Roy Stat Soc 1949; 11: 15-53.
118. Michels P, Mirra J. Attacking the doubling time defense in breast cancer
cases. Medical Trial Technique Quarterly 1981; 28: 301-321.
119. Parver CP. Defence of delayed diagnosis and treatment of breast cancer.
Medical Trial Technique Quarterly 1983; 30: 34-63.
120. Friberg S. 5-year cure rate: Yet another myth. J Surg Oncol 1997; 65: 
73-5.
121. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival
rates evidence of success against cancer? JAMA 2000; 283: 2975-8.
122. Haybittle JL. Curability of breast cancer. Br Med Bull 1990; 47: 319-23.
123. Friberg S. Critical Analysis of Clinical Trials. In: Donegan WL, Spratt JS
(eds.), Cancer of the Breast. Philadelphia: Saunders; 1998.
124. Spratt J. Realities of breast cancer control, public expectations, and
law. Surg Oncol Clin North Am 1994; 3: 25-34.
125. Kern KA. The anatomy of surgical malpractice claims. Bull Am Coll
Surg 1995; 80: 34-9.
126. Bailar III JC and Smith EM. Progress against cancer? N Engl J Med
1986; 314: 1226-32.
127. Bailar III JC, and Gornik HL. Cancer undefeated. N Engl J Med 1997;
336: 1569-74.
128. McKinnon NE. Cancer of the breast: the invalid evidence for faith in
early treatment. Canad J Publ Health 1951; 42: 218-23.
129. Wright CJ, Mueller CB. Screening mammography and public health
policy: the need for perspective. Lancet 1995; 346: 29-32.
130. Gotzsche PC and Olsen O. Is screening for breast cancer with
mammography justifiable? Lancet 2000; 355: 129-34.
131. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer
treatment and survival in hospitals in the United States. Cancer 1999; 86:
1867-76.
132. Eddy DM. Screening for lung cancer. Ann Int Med 1989; 111: 232-7.
133. Spratt JS and Spratt SW. Medical and legal implications of screening and
follow-up procedures for breast cancer. Cancer 1990; 66: 1351-62.
134. McNichols D, Segura J, DeWeerd J. Renal cell carcinoma: Long-term
survival and late recurrence. J Urol 1981; 126: 17-23.
135. Mueller CB: Stage II breast cancer is not simply a late stage I. Surgery
1988; 104: 631-8.
Paper received and accepted: 19 October 2004
22
